PCI-Associated Renal Complications Increase Significantly Among Medicare Patients
CHICAGO, March 29, 2012 /PRNewswire/ — Incidences of renal complications, specifically acute renal failure (ARF) and new hemodialysis (HD), continue to increase significantly among Medicare beneficiaries (MB) admitted for percutaneous coronary intervention (PCI). While patients admitted with impaired renal function are at increased risk, approximately 10 percent of elective patients will suffer renal complications without prior indicators. These findings warrant more focus on implementation of a contrast induced nephropathy (CIN) protocol to reduce complications, according to a study by Cardiac Data Solutions, Inc., presented at the American College of Cardiology 61st Scientific Sessions in Chicago.
The study, conducted from October 1, 2008 to September 30, 2010, was designed to report two-year trends in PCI-associated renal failure. The study group included all Medicare patients admitted for a PCI without CABG surgery or valve surgery in an acute care hospital. The study population was divided into two sub-samples:
- Elective PCI – patients who did not have primary ST Segment Elevation Myocardial Infarction (STEMI) and did not arrive in cardiogenic shock or cardiac arrest.
- Non-Elective PCI – All MBs not undergoing an elective PCI.
All patients studied experienced significant increases in both acute renal failure (ARF) and new hemodialysis (HD) year over year, by 29 percent and 21 percent, respectively. The percentage increase for both complications was slightly higher for those patients undergoing elective PCI, while the increase in ARF among patients undergoing non-elective PCI was nearly double that of elective patients.
“The rise in renal complications is concerning, given their close association with worse morbidity and mortality,” stated April Simon, RN, MSN, one of the researchers and president of Cardiac Data Solutions. “This data suggests that increased focus on contrast induced nephropathy prevention protocols may improve clinical outcomes. Any patient receiving contrast is at risk for CIN; insuring that the amount of contrast is minimized and paying particular attention to hydration are imperative. Often, it’s the simple things that we overlook.”
Other researchers included: Aaron D. Kuglemass, MD, Baystate Health; Phillip P. Brown, MD, Cardiac Data Solutions; Matthew R. Reynolds, MD, Harvard Clinical Research Institute; David J. Cohen, MD, St. Luke’s Mid-America Heart Institute; and Steven D. Culler, PhD, Rollins School of Public Health, Emory University.
About Cardiac Data Solutions, Inc. (CDS)
Founded in 1999, Cardiac Data Solutions, Inc. (CDS) provides consultation services, data analysis, clinical benchmarks, management tools, research support services and leadership training to hospitals, physicians, payors, manufacturers and the financial community. CDS is focused solely on the cardiovascular market with the primary mission of supporting and improving clinical and business decisions to improve the quality of patient care. Using proprietary data analysis tools with comprehensive and current data on clinical outcomes, CDS helps identify opportunities for improvement and develops evidence-based strategies to achieve them. For more information, visit www.cardiacdatasolutions.com.
April W. Simon, RN, MSN
President, Cardiac Data Solutions
SOURCE Cardiac Data Solutions, Inc.